Protalix BioTherapeutics (PLX) Non-Current Assets (2010 - 2026)

Protalix BioTherapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 19.45% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $60.4 million (up 10.65% YoY), while the FY2025 annual figure was $15.7 million, up 17.5% from the prior year.
• Non-Current Assets was $16.0 million for Q1 2026 at Protalix BioTherapeutics, up from $15.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $16.0 million in Q1 2026 to a low of $10.9 million in Q4 2022.
• Historically, Non-Current Assets has averaged $13.5 million across 5 years, with a median of $13.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets declined 10.92% in 2022, then surged 36.55% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $10.9 million in 2022, then jumped by 32.96% to $14.5 million in 2023, then declined by 8.02% to $13.3 million in 2024, then gained by 17.5% to $15.7 million in 2025, then grew by 1.96% to $16.0 million in 2026.
• The last three Non-Current Assets figures came in at $16.0 million (Q1 2026), $15.7 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.